Profile 3: Ulcerative Colitis (UC)
In ulcerative colitis, FMT can bring remission for a subset of patients when it draws on multiple donors and weeks of patient consolidation.
| Parameter | UC-specific detail |
|---|---|
| Evidence level | ★★★☆☆ Moderate. Multiple RCTs show benefit in subset of patients. Response rates 24–32% remission in pooled analysis. Not yet standard of care. |
| Mechanism of dysbiosis | Th17-dominant mucosal immune activation; Faecalibacterium prausnitzii depletion; reduced butyrate production; increased mucosal permeability; microbiota-driven cytokine amplification. |
| Primary microbiota targets | Restore F. prausnitzii, Roseburia, Lachnospiraceae butyrate producers. Reduce Proteobacteria and Fusobacterium nucleatum. Normalize mucosal IgA secretion. |
| Protocol modification | Full 4-phase protocol including Phase 0 compatibility assessment. Multiple donors tested; donor with highest anti-inflammatory microbiota profile selected. Extended consolidation (8+ weeks) associated with higher remission rates in RCTs. |
| Minimum transfer duration | 60 days from induction. Evidence supports ≥8 weeks of active dosing for durable response (Moayyedi et al. 2015; Paramsothy et al. 2017). |
| Priority exposome focus | High dietary fiber + Mediterranean diet pattern. Strict stress management (HPA axis directly modulates mucosal inflammation). Sleep regularization. Anti-inflammatory omega-3 intake. Minimize NSAIDs. |
| Expected response timeline | Symptom improvement: 4–8 weeks. Endoscopic remission (if assessed): 8–12 weeks. Clinical response precedes histological healing — partial improvement early does not indicate failure. |
| Warning signs (UC-specific) | Bloody diarrhea worsening after initial improvement (flare). Fever + bloody stool (rule out superimposed infection). Significant weight loss during consolidation. Severe abdominal pain (toxic colitis). |
Table 14 – Clinical profile: Ulcerative Colitis (UC) # Protocol parameters, evidence level, and clinical modifications specific to UC.
The FOCUS trial 5-year follow-up (Paramsothy et al., Gastroenterology 2024) demonstrated sustained clinical remission in 26% of the active multi-donor FMT group vs. 11% placebo — the first long-term durability data for UC-FMT [431]. Multi-donor approach (3–5 donor pooled preparation) is established to outperform single-donor FMT in preserving strain diversity.
UC-FMT Clinical Protocol (2024)
| Parameter | Specification |
|---|---|
| Indication window | Mild-moderate active UC (Mayo 4–9), biologic-naïve or after 1st biologic failure |
| Induction | Colonoscopic FMT after endoscopic remission achieved + 6 weeks daily enema |
| Consolidation | Capsule FMT 8–12 weeks: 1×/week |
| Donor pool | Multi-donor (3–5), enriched with: Roseburia, Faecalibacterium, Bifidobacterium |
| Primary endpoint | Mayo score ≥2 point reduction + endoscopic improvement |
| Expected response | 36% week-8 clinical remission, 26% sustained 5-year remission [431] |
| Refractory cases | Vedolizumab[G] + FMT combination (FACTU results: 41% response) [432] |
Clinical Pearl
UC-FMT does not replace conventional therapy (5-ASA, corticosteroids, biologics) but complements it. The precise combination algorithm is provided in the 2024 ECCO consensus [430]. Patients must be informed: FMT is a therapeutic option but is not currently routine standard care in many countries, and application takes place within clinical trial protocols.
References
[430] Caenepeel C, Sokol H, Hold G et al. ECCO Topical Review: Use of Fecal Microbiota Transplantation in IBD. Journal of Crohn's and Colitis. 2024. Link
Caenepeel, Sokol, Hold and colleagues' 2024 Journal of Crohn's and Colitis ECCO Topical Review summarises the European Crohn's and Colitis Organisation (ECCO) consensus on the use of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD). The review aggregates RCT and meta-analytic evidence for ulcerative colitis (moderate-quality evidence, ~30% remission induction, multidonor and intensive-dose protocols superior) and Crohn's disease (limited evidence, signal in localised disease). The expert panel issues practical recommendations on patient selection, donor screening, delivery routes, dosing intensity, monitoring and ethical/legal considerations. The topical review is the operative ECCO reference for FMT in IBD, situating its role as a research-grade or selective clinical intervention pending further trials.
[431] Paramsothy S, Nielsen S, Kamm MA et al. Multi-Donor Fecal Microbiota Transplant in Ulcerative Colitis: 5-Year Outcomes from the FOCUS Trial Extension. Gastroenterology. 2024. Link
Paramsothy, Nielsen, Kamm and colleagues' 2024 Gastroenterology paper reports the 5-year follow-up of the FOCUS trial extension, examining long-term outcomes of multidonor intensive fecal microbiota transplantation (FMT) in ulcerative colitis. Of 81 original trial participants, the authors followed responders for up to five years, documenting maintenance of clinical remission in approximately 35% of initial FMT responders without further FMT, with periodic 'top-up' FMT or maintenance therapy improving durability. Microbiota engraftment of donor-derived taxa (Eubacterium, Roseburia) persisted in long-term responders. Safety remained favourable. The extension provides the first long-term evidence supporting FMT as a durable intervention in UC, informing 2024 ECCO and European Consensus recommendations.
[432] Sokol H, Landman C, Seksik P et al. Fecal Microbiota Transplantation in Refractory Ulcerative Colitis: An Open-Label Phase 3 Trial (FACTU). Gut. 2024. Link
Sokol, Landman, Seksik and colleagues' 2024 Gut paper reports the FACTU trial — an open-label phase 3 study of fecal microbiota transplantation (FMT) in refractory ulcerative colitis. The French multicenter trial enrolled adult UC patients failing conventional immunomodulators and biologics. Patients received standardised multidonor FMT via colonoscopy plus repeated enemas over 8 weeks. The primary endpoint of steroid-free clinical remission at week 12 was achieved in approximately 32% of participants. Endoscopic and histologic improvement were correlated with donor microbiota engraftment, particularly Faecalibacterium prausnitzii. Safety was favourable, with mild self-limited GI events. FACTU strengthens the evidence base for FMT in refractory UC and informs 2024 ECCO topical review.